Targeting Glycolysis: Exploring a New Frontier in Glioblastoma Therapy

Overview

Journal Front Immunol

Date 2025 Jan 29

PMID 39877360

Authors

Lu Yang

Sijia Li

Lei Yu

Jiao Leng

Na Li

Affiliations

Soon will be listed here.

Abstract

Glioblastoma(GBM) is a highly malignant primary central nervous system tumor that poses a significant threat to patient survival due to its treatment resistance and rapid recurrence.Current treatment options, including maximal safe surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, have limited efficacy.In recent years, the role of glycolytic metabolic reprogramming in GBM has garnered increasing attention. This review delves into the pivotal role of glycolytic metabolic reprogramming in GBM, with a particular focus on the multifaceted roles of lactate, a key metabolic product, within the tumor microenvironment (TME). Lactate has been implicated in promoting tumor cell proliferation, invasion, and immune evasion. Additionally, this review systematically analyzes potential therapeutic strategies targeting key molecules within the glycolytic pathway, such as Glucose Transporters (GLUTs), Monocarboxylate Transporters(MCTs), Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3), Pyruvate Kinase Isozyme Type M2 (PKM2), and the Lactate Dehydrogenase A (LDHA). These studies provide a novel perspective for GBM treatment. Despite progress made in existing research, challenges remain, including drug penetration across the blood-brain barrier, side effects, and resistance. Future research will aim to address these challenges by improving drug delivery, minimizing side effects, and exploring combination therapies with radiotherapy, chemotherapy, and immunotherapy to develop more precise and effective personalized treatment strategies for GBM.

References

Ortega A, Sanchez-Arago M, Giner-Sanchez D, Sanchez-Cenizo L, Willers I, Cuezva J . Glucose avidity of carcinomas. Cancer Lett. 2008; 276(2):125-35. DOI: 10.1016/j.canlet.2008.08.007. View

Neftel C, Laffy J, Filbin M, Hara T, Shore M, Rahme G . An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019; 178(4):835-849.e21. PMC: 6703186. DOI: 10.1016/j.cell.2019.06.024. View

Wang Z, Wang D, Han S, Wang N, Mo F, Loo T . Bioactivity-guided identification and cell signaling technology to delineate the lactate dehydrogenase A inhibition effects of Spatholobus suberectus on breast cancer. PLoS One. 2013; 8(2):e56631. PMC: 3572989. DOI: 10.1371/journal.pone.0056631. View

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

Li Y, Ge Y, Zhao M, Ding F, Wang X, Shi Z . HSP90B1-mediated plasma membrane localization of GLUT1 promotes radioresistance of glioblastomas. J Biomed Res. 2023; 37(5):326-339. PMC: 10541777. DOI: 10.7555/JBR.37.20220234. View

Blum R, Jacob-Hirsch J, Amariglio N, Rechavi G, Kloog Y . Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res. 2005; 65(3):999-1006. View

Guo D, Tong Y, Jiang X, Meng Y, Jiang H, Du L . Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 2022; 34(9):1312-1324.e6. DOI: 10.1016/j.cmet.2022.08.002. View

Moorhouse A, Spiteri C, Sharma P, Zloh M, Moses J . Targeting glycolysis: a fragment based approach towards bifunctional inhibitors of hLDH-5. Chem Commun (Camb). 2010; 47(1):230-2. DOI: 10.1039/c0cc01166e. View

10.

Daniele S, Giacomelli C, Zappelli E, Granchi C, Trincavelli M, Minutolo F . Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death. Sci Rep. 2015; 5:15556. PMC: 4616042. DOI: 10.1038/srep15556. View

11.

Urbanska K, Orzechowski A . Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells. Int J Mol Sci. 2019; 20(9). PMC: 6539221. DOI: 10.3390/ijms20092085. View

12.

Agnihotri S, Mansouri S, Burrell K, Li M, Mamatjan Y, Liu J . Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells. Clin Cancer Res. 2018; 25(2):844-855. PMC: 8103287. DOI: 10.1158/1078-0432.CCR-18-1854. View

13.

Wang F, Liao W, Li C, Zhu L . Silencing BMAL1 promotes M1/M2 polarization through the LDHA/lactate axis to promote GBM sensitivity to bevacizumab. Int Immunopharmacol. 2024; 134:112187. DOI: 10.1016/j.intimp.2024.112187. View

14.

Mor I, Cheung E, Vousden K . Control of glycolysis through regulation of PFK1: old friends and recent additions. Cold Spring Harb Symp Quant Biol. 2011; 76:211-6. DOI: 10.1101/sqb.2011.76.010868. View

15.

Huang Y, Ouyang F, Yang F, Zhang N, Zhao W, Xu H . The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma. BMC Cancer. 2022; 22(1):900. PMC: 9386956. DOI: 10.1186/s12885-022-10001-y. View

16.

Wang S, Huang T, Wu Q, Yuan H, Wu X, Yuan F . Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 2024; 134(22. PMC: 11563687. DOI: 10.1172/JCI176851. View

17.

Tretter V . Special Issue: Cellular Oxygen Homeostasis. Int J Mol Sci. 2022; 23(9). PMC: 9105186. DOI: 10.3390/ijms23094505. View

18.

Noble R, Bell N, Blair H, Sikka A, Thomas H, Phillips N . Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017; 102(7):1247-1257. PMC: 5566036. DOI: 10.3324/haematol.2016.163030. View

19.

Coyle T, Levante S, Shetler M, Winfield J . In vitro and in vivo cytotoxicity of gossypol against central nervous system tumor cell lines. J Neurooncol. 1994; 19(1):25-35. DOI: 10.1007/BF01051046. View

20.

Li W, Ma X, Li N, Liu H, Dong Q, Zhang J . Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway. Exp Cell Res. 2016; 349(2):320-327. DOI: 10.1016/j.yexcr.2016.11.002. View